FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced positive results from its Canadian pivotal clinical study evaluating the safety and clinical utility of GEM OS®1 Bone Graft for the treatment of foot and ankle fusions. The results demonstrated that 90% of the patients, which included a large percentage of high risk individuals, achieved a successful outcome based upon return to full weight-bearing (FWB) and lack of need for revision surgery. The radiographic fusion rate was 87% at nine months after surgery. The high level of success achieved in this study suggests that the GEM OS1 treated patients had fusion rates comparable to those expected using autogenous bone graft (ABG), the current gold standard for bone grafting materials, but without the morbidity and extra operating room time required to harvest ABG.
